TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Brief Summary: The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)


Options:
A: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing HIV Risk in Female Teens: A Tailored Approach
Brief Summary: The Horizons Program will test the efficacy of a multi-session HIV prevention program for African American female teens attending reproductive health clinics in Atlanta, GA.


Options:
A: Intervention Type: BEHAVIORAL; Name: Intervention with Microfinance for AIDS and Gender Equity; Assigned to Arm(s): N/A
B: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Lecture-format presentation | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive Injection Risk Intervention | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive Sexual Risk Intervention | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive injection and sexual risk intervention | Intervention Type: BEHAVIORAL; Name: Interactive injection and sexual risk intervention; Assigned to Arm(s): Group D | Intervention Type: BEHAVIORAL; Name: Interactive Sexual Risk Intervention; Assigned to Arm(s): Group C | Intervention Type: BEHAVIORAL; Name: Interactive Injection Risk Intervention; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Lecture-format presentation; Assigned to Arm(s): Group A
C: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: HORIZONS HIV Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: enhanced standard-of-care | Intervention Type: BEHAVIORAL; Name: HORIZONS HIV Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: enhanced standard-of-care; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing HIV Risk in Female Teens: A Tailored Approach
Brief Summary: The Horizons Program will test the efficacy of a multi-session HIV prevention program for African American female teens attending reproductive health clinics in Atlanta, GA.


Options:
A: Arm Label: Quadrivalent Human Papillomavirus (HPV) Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Matching Placebo | Intervention Type: BIOLOGICAL; Name: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): Quadrivalent Human Papillomavirus (HPV) Vaccine | Intervention Type: BIOLOGICAL; Name: Matching Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: HORIZONS HIV Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: enhanced standard-of-care | Intervention Type: BEHAVIORAL; Name: HORIZONS HIV Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: enhanced standard-of-care; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
D: Arm Label: SAFE Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SAFE Behavioral Intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: SAFE Behavioral Intervention; Assigned to Arm(s): SAFE Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus
Brief Summary: This study is being conducted to evaluate the safety and effectiveness of lenalidomide (Revlimid®) in subjects with Cutaneous Lupus Erythematosus (CLE). The study drug will be used in an off-label indication to treat 6 subjects for 12 months each. Men and women over the age of 18, who have a biopsy proven diagnosis of CLE and who have failed standard treatment, will be included in the study.


Options:
A: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Arm Label: Lenalidomide 2; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide, Lenalidomide 2
B: Arm Label: A-623 high dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 low dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 high dose every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comparator | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 low dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose every 4 weeks | Intervention Type: OTHER; Name: Placebo Comparator; Assigned to Arm(s): Placebo
C: Arm Label: Part A, 1 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 1 mg/kg CNTO 136 | Arm Label: Part A, 4 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 4 mg/kg CNTO 136 | Arm Label: Part A, 10 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136 | Arm Label: Part B, 10 mg/kg CNTO 136/placebo; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136, Drug: Placebo | Intervention Type: DRUG; Name: 1 mg/kg CNTO 136; Assigned to Arm(s): Part A, 1 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 4 mg/kg CNTO 136; Assigned to Arm(s): Part A, 4 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 10 mg/kg CNTO 136; Assigned to Arm(s): Part A, 10 mg/kg CNTO 136, Part B, 10 mg/kg CNTO 136/placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part B, 10 mg/kg CNTO 136/placebo
D: Arm Label: Abatacept + Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept, Drug: Prednisone | Arm Label: Placebo + Prednisone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Prednisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Abatacept + Prednisone, Placebo + Prednisone | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Determine the Impact of Lymphedema Therapy on Quality of Life and Disease Severity in Patients With Post-Thrombotic Syndrome
Brief Summary: The purpose of this study is to determine if complex lymphedema therapy is effective in decreasing disease severity and improving quality of life in patients with post thrombotic syndrome.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: complex lymphedema therapy | Arm Label: B; Type: OTHER; Interventions: Other: complex lymphedema therapy | Intervention Type: OTHER; Name: complex lymphedema therapy; Assigned to Arm(s): A, B
B: Arm Label: Transdermal Magnesium; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Magnesium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Transdermal Magnesium; Assigned to Arm(s): Transdermal Magnesium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MAGNOX 520®; Type: EXPERIMENTAL; Interventions: Drug: MAGNOX 520® | Arm Label: Similarly looking placebo.; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MAGNOX 520®; Assigned to Arm(s): MAGNOX 520® | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Similarly looking placebo.
D: Arm Label: Physical training - No encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - No encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Arm Label: Physical training - Early encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - Early encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training - Early encephalopathy, Physical training - No encephalopathy | Intervention Type: OTHER; Name: Diet intervention; Assigned to Arm(s): Control - Early encephalopathy, Control - No encephalopathy, Physical training - Early encephalopathy, Physical training - No encephalopathy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder
Brief Summary: This study investigates the hypothesis that instability in mood in patients with borderline personality disorder will respond the mood stabilizing medication lamotrigine.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): therapy | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment
C: Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Teachable Moment Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Teachable Moment Brief Intervention | Intervention Type: BEHAVIORAL; Name: Teachable Moment Brief Intervention; Assigned to Arm(s): Teachable Moment Brief Intervention
D: Arm Label: S-DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Standard dialectical behavior therapy (SDBT) | Arm Label: DBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual DBT with no DBT group sessions (DBT-I) | Arm Label: DBT-S; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Skills DBT with no DBT individual sessions (DBT-S) | Intervention Type: BEHAVIORAL; Name: Standard dialectical behavior therapy (SDBT); Assigned to Arm(s): S-DBT | Intervention Type: BEHAVIORAL; Name: Individual DBT with no DBT group sessions (DBT-I); Assigned to Arm(s): DBT-I | Intervention Type: BEHAVIORAL; Name: Group Skills DBT with no DBT individual sessions (DBT-S); Assigned to Arm(s): DBT-S

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder
Brief Summary: This study investigates the hypothesis that instability in mood in patients with borderline personality disorder will respond the mood stabilizing medication lamotrigine.


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
B: Arm Label: Brexpiprazole 2-3 Milligrams Per Day; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole 2-3 Milligrams Per Day | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: PTSD-EMDR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EMDR | Arm Label: Integrated DBT-EMDR; Type: EXPERIMENTAL; Interventions: Behavioral: EMDR, Behavioral: DBT | Intervention Type: BEHAVIORAL; Name: EMDR; Assigned to Arm(s): Integrated DBT-EMDR, PTSD-EMDR | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Integrated DBT-EMDR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic Fibrosis
Brief Summary: This study is examining the effect of hypertonic saline compared to placebo on the Lung Clearance Index in Cystic Fibrosis patients.


Options:
A: Arm Label: Hypertonic saline; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic Saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hypertonic Saline; Assigned to Arm(s): Hypertonic saline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group A; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group B; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group C; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group D; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group E; Type: N/A; Interventions: Behavioral: Qualitative Interview | Intervention Type: BEHAVIORAL; Name: Qualitative Interview; Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E
C: Arm Label: Pulmozyme; Type: EXPERIMENTAL; Interventions: Drug: Pulmozyme (dornase alfa) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pulmozyme (dornase alfa); Assigned to Arm(s): Pulmozyme | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic Fibrosis
Brief Summary: This study is examining the effect of hypertonic saline compared to placebo on the Lung Clearance Index in Cystic Fibrosis patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
C: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic Fibrosis
Brief Summary: This study is examining the effect of hypertonic saline compared to placebo on the Lung Clearance Index in Cystic Fibrosis patients.


Options:
A: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
C: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic Fibrosis
Brief Summary: This study is examining the effect of hypertonic saline compared to placebo on the Lung Clearance Index in Cystic Fibrosis patients.


Options:
A: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
B: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2
D: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group

Answer: C